BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29492949)

  • 1. Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.
    Lukas RV; Gondi V; Stupp R; Raizer JJ
    Oncology (Williston Park); 2018 Feb; 32(2):e11-e19. PubMed ID: 29492949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
    Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
    Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
    Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
    Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5. Report on workshop: Primary CNS lymphoma.
    Korfel A; Finke J; Schmidt-Wolf I; Thiel E
    Ann Hematol; 2001; 80 Suppl 3():B20-3. PubMed ID: 11757699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
    Kasamon YL; Jones RJ; Piantadosi S; Ambinder RF; Abrams RA; Borowitz MJ; Morrison C; Smith BD; Flinn IW
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):93-100. PubMed ID: 15682069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of primary CNS lymphoma.
    Schmitz N
    Blood; 2015 Feb; 125(9):1360-1. PubMed ID: 25721041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary central nervous system lymphoma: essential points in diagnosis and management.
    Paydas S
    Med Oncol; 2017 Apr; 34(4):61. PubMed ID: 28315229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review].
    Jiang JH; Fang BM; Xu YH
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):162-3. PubMed ID: 23611227
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic challenges in primary CNS lymphoma.
    Morris PG; Abrey LE
    Lancet Neurol; 2009 Jun; 8(6):581-92. PubMed ID: 19446277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary central nervous lymphoma: what is the role for radiotherapy?].
    Bellefqih S; Mezouri I; Khalil J; Bazine A; Diakité A; El Kacimi H; Kebdani T; Benjaafar N
    Cancer Radiother; 2014 Nov; 18(7):685-92. PubMed ID: 25451676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches in primary central nervous system lymphoma.
    Fraser E; Gruenberg K; Rubenstein JL
    Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary CNS lymphoma in immunocompetent patients.
    Sierra del Rio M; Rousseau A; Soussain C; Ricard D; Hoang-Xuan K
    Oncologist; 2009 May; 14(5):526-39. PubMed ID: 19433528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
    Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
    Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
    Provencher S; Ferlay C; Alaoui-Slimani K; Devidas A; Lepretre S; de Prijck B; Sebban C; de la Fouchardiere A; Chassagne-Clement C; Ketterer N; Thyss A; Delannoy A; Tilly H; Biron P; Blay JY; Ghesquières H
    Hematol Oncol; 2011 Mar; 29(1):10-6. PubMed ID: 21381074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis.
    Lukas RV; Stupp R; Gondi V; Raizer JJ
    Oncology (Williston Park); 2018 Jan; 32(1):17-22. PubMed ID: 29447417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
    Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
    Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature.
    Gaut D; Schiller GJ
    Int J Hematol; 2019 Mar; 109(3):260-277. PubMed ID: 30671909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
    Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.